Moving the needle with dual CARs in aggressive lymphomas
New insights on emerging protein degrader classes
Remember how in Monsters, Inc. they discovered laughter generated more power than screams? The oncology world might be on a similar if different revelation with its own monsters.
Time to disrupt the BTK party!
The evolving CAR-T cell therapy landscape in relapsed/refractory multiple myeloma
An increasingly competitive niche is beginning to shake out in early and late stage disease
A rapid evolving field creates challenges for those following the leaders since the SOC can change quickly
The follicular lymphoma niche is changing and becoming more complex
Bispecifics galore! Finding new ways to raise the bar in aggresive lymphomas and myeloma
A review of 14 early stage developments coming soon at ASH24
When the future of ADCs and bispecifics collide
What's hot amongst the up and coming CAR-T cell therapies in early development?
